Centratama Telekomunikasi Indonesia Tbk. (CENT)

Overview

Jaguar Health, Inc. is a commercial stage pharmaceuticals company emphasizing the development of plant-based prescription medicines aimed at treating gastrointestinal distress, particularly chronic and debilitating diarrhea, for both people and animals. Operating through Human Health and Animal Health segments, Jaguar Health prioritizes the development and commercialization of both prescription and non-prescription products for companion and production animals, as well as human products. Headquartered in San Francisco, California, the company has made significant strides in addressing gastrointestinal disorders through innovative, plant-based solutions.

Products and Services

Mytesi: This is an anti-secretory antidiarrheal drug offering symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS who are on antiretroviral therapy. Mytesi represents a pivotal product in Jaguar Health's portfolio, catering to the specific needs of HIV/AIDS patients dealing with the side effects of their antiretroviral treatments.

Canalevia-CA1: A prescription drug product designed specifically for dogs, Canalevia-CA1 targets chemotherapy-induced diarrhea, a common adverse effect experienced by dogs undergoing cancer treatment. This product reflects the company's commitment to extending its plant-based treatment solutions to the veterinary market.

Crofelemer: Currently in Phase 3 clinical trials, Crofelemer is an anti-secretory antidiarrheal drug under development for the prophylaxis of diarrhea in adult cancer patients. It is also being explored for use in rare/orphan disease indications such as short bowel syndrome with intestinal failure and/or congenital diarrheal disorders, diarrhea-predominant irritable bowel syndrome, and idiopathic/functional diarrhea. Crofelemer represents a crucial part of Jaguar Health's pipeline, showcasing its potential in addressing a wide array of gastrointestinal conditions.

NP-300: This second-generation antidiarrheal drug is being developed for the symptomatic relief and treatment of moderate-to-severe diarrhea. Though still in the development phase, NP-300 signifies Jaguar Health’s ongoing efforts to innovate and expand its portfolio of gastrointestinal treatments.